Linassi Federico, Zanatta Paolo, Spano Leonardo, Burelli Paolo, Farnia Antonio, Carron Michele
Department of Pharmaceutical and Pharmacological Sciences, Università Degli Studi di Padova, Via Marzolo 5, 35131 Padova, Italy.
Department of Anesthesiology and Critical Care, Treviso Regional Hospital, AULSS 2 Marca Trevigiana, Piazzale Ospedale 1, 31100 Treviso, Italy.
Life (Basel). 2023 Oct 16;13(10):2065. doi: 10.3390/life13102065.
Various pharmacokinetic/pharmacodynamic (PK/PD) models have been developed to accurately dose propofol administration during total intravenous anesthesia with target-controlled infusion (TIVA-TCI). We aim to clinically compare the performance of the Schnider model and the new and general-purpose Eleveld PK/PD model during TIVA-TCI.
We conducted a prospective observational study at a single center, enrolling 78 female patients, including 37 adults (aged < 65 years) and 41 elderly patients (aged ≥ 65 years). These patients underwent breast surgery with propofol-remifentanil TIVA-TCI guided by the bispectral index (BIS) for depth of anesthesia monitoring (target value 40-60) and the surgical plethysmographic index (SPI) for antinociception monitoring (target value 20-50) without neuromuscular blockade. The concentration at the effect site of propofol (CeP) at loss of responsiveness (LoR) during anesthesia maintenance (MA) and at return of responsiveness (RoR), the duration of surgery and anesthesia (min), the time to RoR (min), the propofol total dose (mg), the deepening of anesthesia events (DAEs), burst suppression events (BSEs), light anesthesia events (LAEs) and unwanted spontaneous responsiveness events (USREs) were considered to compare the two PK/PD models.
Patients undergoing BIS-SPI-guided TIVA-TCI with the Eleveld PK/PD model showed a lower CeP at LoR (1.7 (1.36-2.25) vs. 3.60 (3.00-4.18) μg/mL, < 0.001), higher CePMA (2.80 (2.55-3.40) vs. 2.30 (1.80-2.50) μg/mL, < 0.001) and at RoR (1.48 (1.08-1.80) vs. 0.64 (0.55-0.81) μg/mL, < 0.001) than with the Schnider PK/PD model. Anesthetic hysteresis was observed only in the Schnider PK/PD model group ( < 0.001). DAEs (69.2% vs. 30.8%, = 0.001) and BSEs (28.2% vs. 5.1%, = 0.013) were more frequent with the Eleveld PK/PD model than with the Schnider PK/PD model in the general patient population. DAEs (63.2% vs. 27.3%, = 0.030) and BSEs (31.6% vs. 4.5%, = 0.036) were more frequent with the Eleveld PK/PD model than with the Schnider PK/PD model in the elderly.
The Schnider and Eleveld PK/PD models impact CePs differently. A greater incidence of DAEs and BSEs in the elderly suggests more attention is necessary in this group of patients undergoing BIS-SPI-guided TIVA-TCI with the Eleveld PK/PD than with the Schnider model.
已经开发了各种药代动力学/药效学(PK/PD)模型,以在靶控输注全静脉麻醉(TIVA-TCI)期间准确地给予丙泊酚剂量。我们旨在临床上比较Schnider模型和新型通用Eleveld PK/PD模型在TIVA-TCI期间的性能。
我们在单一中心进行了一项前瞻性观察性研究,纳入78名女性患者,包括37名成年人(年龄<65岁)和41名老年患者(年龄≥65岁)。这些患者在脑电双频指数(BIS)用于麻醉深度监测(目标值40-60)和外科体积描记指数(SPI)用于抗伤害感受监测(目标值20-50)的引导下,接受丙泊酚-瑞芬太尼TIVA-TCI进行乳房手术,未使用神经肌肉阻滞剂。记录麻醉维持(MA)期间意识消失(LoR)时和意识恢复(RoR)时丙泊酚效应室浓度(CeP)、手术和麻醉持续时间(分钟)、至RoR的时间(分钟)、丙泊酚总剂量(毫克)、麻醉加深事件(DAEs)、爆发抑制事件(BSEs)、浅麻醉事件(LAEs)和意外的自主反应事件(USREs),以比较两种PK/PD模型。
与Schnider PK/PD模型相比,使用Eleveld PK/PD模型进行BIS-SPI引导的TIVA-TCI的患者在LoR时CeP较低(1.7(1.36-2.25)与3.60(3.00-4.18)μg/mL,<0.001),MA时CeP较高(2.80(2.55-3.40)与2.30(1.80-2.50)μg/mL,<0.001),RoR时CeP也较高(1.48(1.08-1.80)与0.64(0.55-0.81)μg/mL,<0.001)。仅在Schnider PK/PD模型组中观察到麻醉滞后(<0.001)。在普通患者群体中,与Schnider PK/PD模型相比,Eleveld PK/PD模型的DAEs(69.2%对30.8%,=0.001)和BSEs(28.2%对5.1%,=0.013)更频繁。在老年患者中,与Schnider PK/PD模型相比,Eleveld PK/PD模型的DAEs(63.2%对27.3%,=0.030)和BSEs(31.6%对4.5%,=0.036)更频繁。
Schnider和Eleveld PK/PD模型对CeP的影响不同。老年患者中DAEs和BSEs的发生率更高,这表明在使用Eleveld PK/PD模型进行BIS-SPI引导的TIVA-TCI的这组患者中,比使用Schnider模型时需要更多关注。